Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Soo-Chin Lee,Noriko Shimasaki,Joline S.J. Lim,Andrea Wong,Kritika Yadav,Wei Peng Yong,Lip Kun Tan,Liang Piu Koh,Michelle L.M. Poon,Sing Huang Tan,Samuel G.W. Ow,Lavina Bharwani,Yoon Sim Yap,Mabel Z.Q. Foo,Elaine Coustan-Smith,Raghav Sundar,Wan Qin Chong,Nesaretnam Barr Kumarakulasinghe,Jedidah L.M. Lieow,Priscillia J.X. Koe,Boon Cher Goh,Dario Campana,Hon Lyn Tan
DOI: https://doi.org/10.1158/1078-0432.ccr-20-0768
IF: 13.801
2020-09-02
Clinical Cancer Research
Abstract:Purpose: Natural killer (NK) cells exert antibody-dependent cell cytotoxicity (ADCC). We infused expanded, activated autologous NK cells to potentiate trastuzumab-mediated ADCC in patients with HER2-positive malignancies. Patients and Methods: In a phase I trial, patients with treatment-refractory HER2-positive solid tumors received trastuzumab, with or without bevacizumab, and autologous NK cells expanded by 10-day coculture with K562-mb15-41BBL cells. Primary objectives included safety and recommended phase II dose determination; secondary objectives included monitoring NK-cell activity and RECIST antitumor efficacy. Results: In 60 cultures with cells from 31 subjects, median NK-cell expansion from peripheral blood was 340-fold (range, 91–603). NK cells expressed high levels of CD16, the mediator of ADCC, and exerted powerful killing of trastuzumab-targeted cells. In the 22 subjects enrolled in phase I dose escalation, trastuzumab plus NK cells were well tolerated; MTD was not reached. Phase IB ( n = 9) included multiple cycles of NK cells (1 x 10 7 /kg) and addition of bevacizumab. Although no objective response was observed, 6 of 19 subjects who received at least 1 x 10 7 /kg NK cells at cycle 1 had stable disease for ≥6 months (median, 8.8 months; range 6.0–12.0). One patient, the only one with the high-affinity F158V CD16 variant, had a partial response. Peripheral blood NK cells progressively downregulated CD16 postinfusion; paired tumor biopsies showed increased NK cells, lymphocytic infiltrates, and apoptosis posttreatment. Conclusions: NK-cell therapy in combination with trastuzumab was well tolerated, with target engagement and preliminary antitumor activity, supporting continued assessment of this approach in phase II trials.
oncology